Organism: Homo sapiens
Gene: 1552923_a_at
Selected probe(set): 1552924_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552923_a_at (1552924_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.1984253
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):4.190645
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):3.271348
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):3.2165422
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.4876986
Number of Samples:75 / 441

Experimental	CML study 1
	Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Relative Expression (log2-ratio):2.4503298
Number of Samples:36 / 74

Experimental	precursor-B-ALL study 1 (t(1;19)(q23,q13))
	Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):2.324314
Number of Samples:441 / 74

Experimental	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):2.2966013
Number of Samples:2 / 27

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):2.011427
Number of Samples:2 / 21

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (TEL-AML1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-2.0010967
Number of Samples:4 / 2

Experimental	precursor-B-ALL study 2 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).